Losing 4 pounds in a week isn’t unheard of, but it’s not usually considered a safe or sustainable strategy for weight loss.

Subcutaneous injections of an investigational, selective long-acting amylin receptor agonist led to clinically meaningful ...

A small new study suggests that people who’ve used GLP-1 drugs to reach a healthy weight can spread out their injections ...

The drugmaker said it would launch late-stage trials of the drug after participants lost as much as 20% of their body weight.

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

Amylin is a peptide co-secreted with insulin in response to food intake. It controls gastric emptying, inhibits glucagon secretion, and promotes satiety. Several amylin receptor agonists are in ...

The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.

Eli Lilly said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging ...

Early weight loss of 2%-3% within 4 weeks is significantly linked to achieving clinically significant weight loss at 16 weeks ...

Once-weekly semaglutide 2.4 mg conferred a greater reduction in major adverse cardiovascular events than placebo, regardless ...

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...